Eli Lilly's $2B Onswik FDA Approval Revolutionizes Diabetes | Pharma and Biotech Daily
Friday, September 25, 2026
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of recent breakthroughs and strategic moves that are shaping the future of drug development and patient care.
Eli Lilly has achieved a significant milestone with the FDA's approval of Onswik, a once-weekly insulin therapy for type 2 diabetes. This innovative treatment is set to revolutionize diabetes management by offering a more convenient regimen, which could improve patient compliance and outcomes. Supported by robust phase 3 clinical trial data, Onswik is a testament to the importance of protein therapies in tackling metabolic diseases, highlighting Eli Lilly's commitment to advancing diabetes care. Additionally, Eli Lilly's collaboration with InnoCare Pharma exemplifies the trend of strategic partnerships playing an increasingly crucial role in accelerating drug discovery and development, focusing on five unmet medical targets with substantial financial milestones.
In oncology, Elevar Therapeutics has received FDA approval for Lirafugratinib, a small molecule FGFR inhibitor targeting FGFR2-altered cholangiocarcinoma. This approval is a beacon of hope for patients with this challenging cancer type, emphasizing the potential of personalized medicine approaches in oncology. In another significant development, Elevar Therapeutics' FDA approval for Lyrfigtu marks a notable achievement as the first novel cancer drug from a Korean company to enter the U.S. market. This milestone underscores the global expansion of drug development capabilities and highlights Asian biopharmaceutical companies' growing influence.
Promising clinical trial results continue to emerge. Merck's Remigromig demonstrated efficacy in a phase 2b/3 trial for diabetic macular edema as a Wnt pathway agonist, offering a novel approach in ophthalmology that could expand treatment options beyond VEGF pathways. In autoimmune diseases, Kyverna Therapeutics reported durable efficacy and safety for Mivocabtagene autoleucel in phase 3 trials for stiff person syndrome. This progress showcases the potential of CAR-T cell therapies in areas beyond oncology.
Funding activities also highlight the sector's dynamism, with companies like Basecamp Research and BigHat Biosciences securing significant investments to advance AI-driven drug discovery platforms. These initiatives underscore the growing integration of artificial intelligence and machine learning in biopharmaceutical research—innovations that promise to expedite the identification and optimization of therapeutic candidates.
On the regulatory front, Grail's Galleri multi-cancer blood test received positive recommendations from an FDA advisory committee. This liquid biopsy diagnostic holds promise for early cancer detection and screening advancements in precision medicine strategies in oncology. However, not all news is positive; Acadia Pharmaceuticals faced setbacks as its phase 2 trial for Remlifanserin missed primary endpoints in Alzheimer's disease psychosis, illustrating the challenges inherent in neurological drug development.
Industry dynamics are further illustrated by Boehringer Ingelheim's strategic decision to offload its Shanghai CDMO to RAAS Blood Products, reflecting ongoing localization trends within pharmaceutical manufacturing. Meanwhile, AstraZeneca's Breztri received its third asthma-related approval from the European Commission, reinforcing its commitment to expanding its respiratory portfolio across key geographies.
Additionally, legal actions such as the Florida Attorney General's lawsuit against three drug manufacturers and PBMs over alleged insulin price inflation highlight ongoing concerns about drug pricing. These actions may prompt further scrutiny and potential regulatory reforms within the pharmaceutical supply chain.
Agentic AI is emerging as a pivotal trend in clinical trials, offering new models for connecting workflows and accelerating trial execution—a crucial advancement amid increasing trial complexity. Collectively, these developments illustrate an industry characterized by scientific innovation, strategic alliances, and regulatory achievements—all aimed at improving patient care and expanding access to novel therapies.
As technological innovations like AI reshape clinical trials and companies navigate complex regulatory landscapes, the potential for breakthroughs in drug development remains high. These trends have profound implications for patient outcomes and the future direction of pharmaceutical research and development. Stay tuned as we continue to bring you more updates on these exciting advancements in our next episode.